El interés en corto de Archer Aviation da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Archer Aviation. Los datos de interés en corto se actualizan cada dos semanas.

Archer Aviation (NYSE:ACHR) Bolsa, Informe de interés en corto

Archer Aviation

Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.

Equities

News

ETFs

ACHR

ARKK

PLTR

QCOM

RBLX

Ark Invest vendió acciones de Palantir por 10,4M$. ¿Qué impulsó esta decisión y qué significa para los inversionistas?

Ark Invest ajusta su portafolio: venta masiva de Palantir y nuevas compras estratégicas

Archer Aviation Inc. Class A Common Stock

Archer Aviation Inc

Archer Aviation Inc. Redeemable Warrants, each whole warrant exercisable for one Class A common stock at an exercise price of $11.50

Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) reported quarterly earnings of $6.45 per share which missed the analyst consensus estimate of $7.62 by 15.35 percent. This is a 60.48 percent decrease over earnings of $16.32 per share from the same period last year. The company reported quarterly sales of $3.85 billion which missed the analyst consensus estimate of $3.93 billion by 1.91 percent. This is a 5.48 percent increase over sales of $3.65 billion the same period last year.

Earnings

Earnings Misses

Everest Group Q1 Adj. EPS $6.45 Misses $7.62 Estimate, Sales $3.85B Miss $3.93B Estimate

Seacor Marine Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMHI#NYSE">SMHI</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 35.71 percent increase over losses of $(0.84) per share from the same period last year. The company reported quarterly sales of $55.50 million which missed the analyst consensus estimate of $65.30 million by 15.01 percent. This is a 11.58 percent decrease over sales of $62.77 million the same period last year.

Earnings Beats

SMHI

Seacor Marine Hldgs Q1 EPS $(0.54) Beats $(0.57) Estimate, Sales $55.50M Miss $65.30M Estimate

Carriage Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSV#NYSE">CSV</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.83 by 15.66 percent. This is a 28 percent increase over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $101.70 million which missed the analyst consensus estimate of $102.25 million by 0.53 percent. This is a 1.73 percent decrease over sales of $103.49 million the same period last year.

Carriage Servs Q1 Adj. EPS $0.96 Beats $0.83 Estimate, Sales $101.70M Miss $102.25M Estimate

Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.77 by 22.08 percent. This is a 25.98 percent decrease over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $2.92 billion which missed the analyst consensus estimate of $2.93 billion by 0.21 percent. This is a 15.11 percent decrease over sales of $3.44 billion the same period last year.

Tenaris Q1 GAAP EPS $0.94 Beats $0.77 Estimate, Sales $2.92B Miss $2.93B Estimate

Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) ("Wellchange Holdings Company" or the "Company") is an enterprise software solution services provider headquartered in Hong Kong with diversified expansion strategies, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq") on April 28, 2025, indicating that the Company is not in compliance with Nasdaq's minimum bid price requirement.
Nasdaq Listing Rule 5550(a)(2) requires that listed securities maintain a minimum bid price of $1.00 per share. The notification letter stated that the Company's ordinary shares have failed to maintain this minimum bid price for the last 33 consecutive business days, from March 11, 2025, to April 25, 2025.

Wellchange Holdings Receives Nasdaq Non-Compliance Notice For Minimum Bid Price Requirement

Financing

APLD

Applied Digital Enters $150M Convertible Preferred Equity Facility With Institutional Investors

Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.97 by 13.4 percent. This is a 36.05 percent decrease over earnings of $1.72 per share from the same period last year. The company reported quarterly sales of $1.01 billion which missed the analyst consensus estimate of $1.04 billion by 2.83 percent. This is a 38.39 percent decrease over sales of $1.64 billion the same period last year.

Crown Castle Q1 FFO $1.10 Beats $0.97 Estimate, Sales $1.01B Miss $1.04B Estimate

Management

EBAY

eBay's CFO Steve Priest To Leave The Company. Peggy Alford Will Join As The Company's CFO, Effective May 12.

Abeona Therapeutics Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) stock traded <a href="https://www.benzinga.com/general/biotech">higher on Wednesday.</a>
The Food and Drug Administration (FDA) on Tuesday approved Abeona&#8217;s Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">epidermolysis bullosa (RDEB)</a>.
Zevaskyn is the only FDA-approved product to treat RDEB wounds&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45080457/abeona-therapeutics-wins-fda-approval-for-first-of-its-kind-gene-therapy" rel="noreferrer noopener">with a single application</a>.
Zevaskyn consists of a patient's skin cells (keratinocytes) genetically modified to produce functional Type VII collagen. Zevaskyn sheets are surgically applied to the patient's wounded areas. In a single application, up to 12 credit card-sized sheets can be combined to cover large areas or applied to multiple distinct wounds, allowing for significant coverage of affected body areas.
HC Wainwright writes the approval was granted on time, showing that the agency can still meet deadlines despite recent disruptions. Analyst Raghuram Selvaraju on Wednesday wrote that pz-cel is well-positioned to become the leading treatment for the most severe cases of recessive dystrophic epidermolysis bullosa (RDEB).
It may also be used on its own or alongside other approved treatments like Krystal Biotech, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) Vyjuvek (beremagene geperpavec) in certain patients.
On Monday, the European Commission approved Vyjuvek for wounds in patients with dystrophic epidermolysis bullosa who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45034979/krystal-biotech-announces-european-commission-approval-of-vyjuvek-for-the-treatment-of-dystrophic-" rel="noreferrer noopener">starting from birth</a>.
<ul>
<li>The timing for the availability of VYJUVEK in individual countries will depend on multiple factors, including the completion of reimbursement procedures.</li>
<li>The company is planning for its first European launch in Germany in mid-2025.</li>
</ul>
The list price for Zevaskyn has been revealed at $3.1 million per treatment, much higher than the $800,000 we previously assumed, the analyst said.
Based on this new price, the analyst estimates that treating 10–15 patients by the end of 2025 could bring Abeona over $30 million in sales.
HC Wainwright&#8217;s updated revenue forecast for 2025 is now $31.6 million, increasing to $130.4 million in 2026.
HC Wainwright continues to project peak U.S. sales of around $600 million. Abeona believes there are about 750 potential patients in the target population, which could mean a market opportunity of over $2 billion if all were treated with Zevaskyn.
Analyst Selvaraju <a target="_blank" href="https://www.benzinga.com/quote/ABEO/analyst-ratings" rel="noreferrer noopener">maintains the Buy rating</a> and raise the price target from $15 to $20 per share, reflecting increased confidence in the drug.
Price Action: ABEO stock was up 23.77% to $6.56 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45108703/fresh-del-monte-stock-falls-as-q1-sales-earnings-miss-expectations" target="_blank" rel="noreferrer noopener">Fresh Del Monte Stock Falls As Q1 Sales, Earnings Miss Expectations</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

ABEO

KRYS

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Office Props IT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.30 by 80 percent. This is a 92.41 percent decrease over earnings of $0.79 per share from the same period last year. The company reported $113.61 million in sales this quarter. This is a 18.52 percent decrease over sales of $139.44 million the same period last year.

Office Props IT Q1 FFO $0.06 Misses $0.30 Estimate, Sales $113.61M Down From $139.44M YoY

Deluxe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLX#NYSE">DLX</a>) affirms FY2025 Adj EPS guidance from $3.25-$3.55 to $3.25-$3.55 vs $3.31 analyst estimate. Affirms FY2025 sales outlook from $2.09 billion-$2.15 billion to $2.09 billion-$2.15 billion vs $2.12 billion estimate.

Guidance

Deluxe Affirms FY2025 Adj EPS Guidance of $3.25-$3.55 vs $3.31 Est; Affirms FY2025 Sales Guidance of $2.09B-$2.15B vs $2.12B Est

JKHY

Jack Henry & Associates Q3 Deconversion Revenue $9.6M

Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.21 by 4.76 percent. This is a 8.33 percent decrease over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $184.48 million which beat the analyst consensus estimate of $184.04 million by 0.24 percent. This is a 1.95 percent decrease over sales of $188.14 million the same period last year.

Summit Hotel Properties Q1 FFO $0.22 Beats $0.21 Estimate, Sales $184.48M Beat $184.04M Estimate

RBC Capital Markets analyst Daniel R. Perlin reiterated his Outperform rating on Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) on Wednesday, <a href="https://www.benzinga.com/quote/V/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price forecast of $395.</a>
On Tuesday, Visa reported second-quarter earnings of&nbsp;$2.76&nbsp;per share, which beat the analyst consensus estimate of&nbsp;$2.68. Quarterly revenue came in at $9.59 billion,&nbsp;which beat the analyst consensus estimate of&nbsp;$9.55 billion.
Perlin noted that, despite ongoing market uncertainty, Visa&#8217;s results provide insight into consumer health, with adjusted U.S. spending volumes remaining steady in the fiscal second quarter and through April 28, although some category shifts and a slight slowdown in cross-border activity were observed.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45098350/mastercard-vs-visa-two-giants-one-payment-war-whos-ready-to-outperform" rel="noreferrer noopener">Mastercard Vs. Visa: Two Giants, One Payment War — Who&#8217;s Ready To Outperform?</a>
While there are some minor positives and negatives, full-year 2025 guidance remains unchanged, with management prepared to adjust if the data warrants it.
Perlin pointed to three positives from Visa's results: First, payment volumes remained strong, with only a slight deceleration in fiscal Q2, and U.S. volumes improved in April, indicating steady consumer spending. Second, value-added services revenue grew 22% year over year, with gains in Pismo and Featurespace suggesting added resilience beyond spending cycles.
Lastly, Visa announced a new $30 billion share repurchase program.
Taking the latest results and outlook into account, the analyst updated his forecasts for FY25 and FY26, maintaining revenue estimates at $39.5 billion and $43.8 billion while slightly raising adjusted EPS for FY25 to $11.30 from $11.20 and keeping FY26 EPS steady at $12.75.
Price Action: V shares are trading higher by 0.49% to $343.18 at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45096783/visa-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-wednesday" target="_blank" rel="noreferrer noopener">Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>
Photo: Shutterstock

Markets

Visa's Q2 Results Reflect Steady US Spending Despite Market Uncertainty: Analyst Highlights Strength In Payment Volumes

Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) affirms FY2025 FFO guidance from $1.03-$1.07 to $1.03-$1.07 vs $1.06 analyst estimate..

Whitestone REIT Affirms FY2025 FFO Guidance of $1.03-$1.07 vs $1.06 Est

Deluxe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLX#NYSE">DLX</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.71 by 5.63 percent. This is a 1.32 percent decrease over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $536.50 million which beat the analyst consensus estimate of $525.42 million by 2.11 percent. This is a 0.28 percent increase over sales of $535.00 million the same period last year.

Deluxe Q1 Adj. EPS $0.75 Beats $0.71 Estimate, Sales $536.50M Beat $525.42M Estimate

Morguard REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRT#TSX">MRT</a>) reported quarterly earnings of $0.01 per share. This is a 90.91 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $60.35 million in sales this quarter. This is a 6.29 percent decrease over sales of $64.40 million the same period last year.

TSX:MRT

Morguard REIT Q1 FFO $0.01 Down From $0.11 YoY, Sales $60.35M Down From $64.40M YoY

The Board of Directors of Atkore Inc. (the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>), a leading manufacturer of electrical products for commercial, industrial, data center, telecommunications, and solar applications, today approved an increase in the Company's quarterly cash dividend from $0.32 to $0.33 per share of common stock. The dividend increase will be effective for quarterly dividends payable on May 28, 2025, to stockholders of record on May 16, 2025.

Dividends

ATKR

Atkore Increases Quarterly Cash Dividend From $0.32 To $0.33 Per Share

Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) reported quarterly earnings of $0.25 per share which missed the analyst consensus estimate of $0.26 by 3.85 percent. This is a 8.7 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $38.00 million which missed the analyst consensus estimate of $39.10 million by 2.80 percent. This is a 2.26 percent increase over sales of $37.16 million the same period last year.

Whitestone REIT Q1 FFO $0.25 Misses $0.26 Estimate, Sales $38.00M Miss $39.10M Estimate

Fiscal 2025 Outlook
The below outlook assumes no meaningful changes in business activities resulting from the evolving tariff and trade negotiations.
Fourth Quarter Fiscal 2025
UNIFI expects the following fourth quarter fiscal 2025 results:
<ul>
<li>Net sales and Adjusted EBITDA&#x2A;&#x2A; improving sequentially from the third quarter of fiscal 2025, primarily driven by further recovery for the Americas Segment.</li>
<li>Continued restructuring and transition expenses, primarily equipment relocation and abandonment costs, of between $6.0 million and $8.0 million.</li>
<li>Continued volatility in the effective tax rate.</li>
</ul>

UNIFI Expects Net Sales And Adjusted EBITDA Improving Sequentially From Q3 Of Fiscal 2025, Primarily Driven By Further Recovery For The Americas Segment.

Press Releases

Archer To Report Fourth Quarter and Full Year 2024 Operating Update and Financial Results on February 27, 2025

Archer Receives FAA Certification To Launch Its Pilot Training Academy

Archer Unveils Midnight "Launch Edition" Commercialization Program with Abu Dhabi Aviation (ADA) As First Customer Planning to Deploy Midnight This Year

Archer Announces Fourth Quarter & Full Year 2024 Results, Sets Plans For Midnight Commercial Deployments Ahead Of FAA Certification

Archer and Palantir to Build the AI Foundation for the Future of Next-Gen Aviation Technologies

Ethiopian Airlines, Africa's Largest Carrier, and Archer Sign Agreement to Deploy Midnight Under the "Launch Edition" Program

Drone Surveying Market One of The Fastest Growing Segments of the Drone Industry as Revenue Opportunity Climbs

Archer Unveils Vision for New York Air Taxi Network, Including Routes Between Manhattan and Nearby Airports in Partnership with United Airlines

Archer Secures Design Approval For UAE's First Hybrid Heliport, Paving The Way For Commercial Air Taxi Service In Abu Dhabi

Archer To Report First Quarter 2025 Operating Update and Financial Results on May 12, 2025

BMV:ZENA

RCAT

ZENA

AeroVironment

BWX Technologies

Cadre Hldgs

Leonardo DRS

EHang Holdings

Embraer

Eve Holding

Huntington Ingalls Industries, Inc. Common Stock

Huntington Ingalls Indus

Hexcel

Karman Holdings

Kratos Defense & Security Solutions, Inc. - Common Stock

Kratos Defense & Security

Loar Holdings

Intuitive Machines, Inc. - Class A Common Stock

Intuitive Machines

Moog Inc. Class A Common Stock

Moog Inc. Class B Common Stock

Mercury Sys

Redwire

Rocket Lab USA

StandardAero

Spirit Aerosystems Holdings, Inc. Common Stock

Spirit AeroSystems Hldgs

Triumph Group

Textron

Woodward

Needham

Canaccord Genuity

HC Wainwright & Co.

Raymond James

JP Morgan

Screenshot 2024-06-28 at 7.01.02 PM

Emerging Markets

Movers & Shakers

HOVR

The Future Of Air Mobility: Horizon Aircraft&#39;s Cavorite X7 Leading The Charge In eVTOL Innovation

Screenshot 2024-05-30 at 6.26.23 PM

JOBY

LILM

New Horizon Aircraft (NASDAQ: HOVR) Announces Key Technical Updates On Development Of eVTOL Prototype

Comments

Archer Aviation

Interés en corto

Archer Aviation (NYSE:ACHR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL